Angiotensin Converting Enzyme (ACE) Inhibitors Market 2028 By Product, Indication, Distribution Channel, and Geography | The Insight Partners

report image

Angiotensin Converting Enzyme (ACE) Inhibitors Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Others ); Indication (Cardiovascular Diseases, Hypertension, Chronic Kidney Diseases, Diabetes, Scleroderma, Migraines); Distribution Channel (Online Pharmacies, Retail and Hospital Pharmacies), and Geography

Report Code: TIPRE00020853 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

MARKET INTRODUCTION

Angiotensin converting enzyme inhibitors (ACE inhibitors) are used as medicines to inhibit the enzyme ACE activity. It decreases angiotensin II production that results in the enlargement of blood vessels and blood pressure is reduced. This further lower blood pressure and makes it easier for the heart to pump blood and reduce heart failure chances. In addition, ACE inhibitors help in slowing down the progression of kidney disease due to high blood pressure or diabetes.

MARKET DYNAMICS

The angiotensin converting enzyme (ACE) inhibitors market growth is estimated to grow due to the increasing incidences of cardiovascular and kidney diseases, hypertension and other such chronic conditions. The market is also expected to due to growing biopharmaceutical product development and production. The emerging markets such as Asia Pacific, Middle East and Africa, and South and Central America are likely to serve growth opportunities for the market's growth.

MARKET SCOPE

The "Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of angiotensin converting enzyme (ACE) inhibitors market with detailed market segmentation by product, indication, and distribution channel. The angiotensin converting enzyme (ACE) inhibitors market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in angiotensin converting enzyme (ACE) inhibitors market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The angiotensin converting enzyme (ACE) inhibitors market is segmented on the basis of enzyme product, indication, and distribution channel. Based on product, the market is classified as benazepril, captopril, enalapril, fosinopril, lisinopril, and others. On the basis of indication, the market is segmented as cardiovascular diseases, hypertension, chronic kidney diseases, diabetes, scleroderma, and migraines. And based on the distribution channel, the market is segmented as online pharmacies, retail and hospital pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the angiotensin converting enzyme (ACE) inhibitors market based on various segments. It also provides market size and forecast estimates from year 2021 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America (SCAM). The angiotensin converting enzyme (ACE) inhibitors market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting angiotensin converting enzyme (ACE) inhibitors market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the angiotensin converting enzyme (ACE) inhibitors market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the angiotensin converting enzyme (ACE) inhibitors market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from angiotensin converting enzyme (ACE) inhibitors market are anticipated to have lucrative growth opportunities in the future with the rising demand for angiotensin converting enzyme (ACE) inhibitors market in the global market. Below mentioned is the list of few companies engaged in the angiotensin converting enzyme (ACE) inhibitors market.

The report also includes the profiles of key players in angiotensin converting enzyme (ACE) inhibitors market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •   Novartis AG
  •   Pfizer, Inc
  •   Merck & Co., Inc.
  •   Bristol Myers Squibb
  •   Astra and Zeneca
  •   UCB (Schwarz Pharma Inc.)
  •   Solvay Pharmaceuticals B.V.
  •   Abbott
  •   Endo International (Par Pharmaceutical, Inc.)
  •   Sanofi

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

The List of Companies

1. Novartis AG
2. Pfizer, Inc
3. Merck & Co., Inc.
4. Bristol Myers Squibb
5. Astra and Zeneca
6. UCB (Schwarz Pharma Inc.)
7. Solvay Pharmaceuticals B.V.
8. Abbott
9. Endo International (Par Pharmaceutical, Inc.)
10. Sanofi
11. Johnson & Johnson Services, Inc.
12. Perrigo Company plc
13. United Therapeutics Corporation
14. Daiichi Sankyo Company, Ltd
15. Bayer AG
TIPRE00020853
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




christmas_festive_offer

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000 $2700
  • $4550 $4095
  • $6550 $5568
  • $8550 $6840

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount